CClinicalTrials.gg
RecruitingNCT07228364PIONEER-PKDUpdated Sep 11, 2026

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

A Phase 1 interventional study of AZD1613 - Part A and Placebo - Part A in Autosomal Dominant Polycystic Kidney Disease, sponsored by AstraZeneca. Recruiting at 15 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A study to investigate safety, tolerability, and pharmacokinetics of AZD1613 following subcutaneous or intravenous administration in participants with autosomal dominant polycystic kidney disease (ADPKD).

Read the detailed description

This Phase I, randomised, single-blind, placebo-controlled study will assess the safety and tolerability of AZD1613 and characterise the pharmacokinetics (PK) of AZD1613 in participants with autosomal dominant polycystic kidney disease (ADPKD), following subcutaneous (SC) or intravenous (IV) administration. Inclusion of participants receiving placebo is appropriate for benchmarking the safety and tolerability of AZD1613. Furthermore, the safety and PK profile will be evaluated in Chinese participants with ADPKD to assess any potential race effect in this population.

02

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with ADPKD Mayo Class (IB-IE), as per clinical diagnosis (MIC) assessed centrally. Genetic testing results will not be used for eligibility purposes
  • eGFR = 45 to 90 mL/min /1.73m2
  • Body weight ≥ 45 kg and body mass index within the range 18 to 35 kg/m2 (inclusive).
  • Females are to be of non-childbearing potential

Exclusion criteria

Exclusion Criteria:

  • As judged by the investigator, any evidence of cardiac, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the participant to participate in the study.
  • Positive hepatitis C antibody, hepatitis B virus surface antigen, or human immunodeficiency virus test, at screening.
  • History of QT prolongation associated with other medications that required discontinuation of that medication.
  • Congenital long QT syndrome.
  • History of ventricular arrhythmia requiring treatment. Patients with atrial fibrillation/flutter and controlled ventricular rate HR \< 100 bpm can be eligible as judged by the investigator.
  • Haemoglobin below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.
  • Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.
  • Systolic BP > 160 mmHg or diastolic BP > 100mmHg or HR \< 50 bpm or > 100 bpm at screening. Patients taking anti-hypertensive medication should be on a stable treatment regimen of antihypertensive therapy for at least 30 days prior to the screening visit.
  • Any clinically important abnormalities in rhythm, conduction, or morphology of the resting ECG and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of QTc interval changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.
  • Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Part A - Cohort A1

    Participants will receive 4 doses of AZD1613 or placebo on days 1, 29, 57 and 85.

    Drug: AZD1613 - Part A · Drug: Placebo - Part A

  • Experimental
    Part A - Cohort A2

    Participants will receive 4 doses of AZD1613 or placebo on days 1, 29, 57 and 85.

    Drug: AZD1613 - Part A · Drug: Placebo - Part A

  • Experimental
    Part B - Chinese Cohort

    Participants will receive 4 doses of AZD1613 or placebo on days 1, 29, 57 and 85.

    Drug: AZD1613 - Part A · Drug: AZD1613 - Part B · Drug: Placebo - Part B

Interventions

  • DrugAZD1613 - Part A

    Part A - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.

  • DrugPlacebo - Part A

    Part A - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.

  • DrugAZD1613 - Part B

    Part B - Participants will be administered doses of AZD1613 on days 1, 29, 57, and 85 according to randomization in IRT.

  • DrugPlacebo - Part B

    Part B - Participants will be administered doses of placebo on days 1, 29, 57, and 85 according to randomization in IRT.

05

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    Number of participants with at least one TEAE and SAE, including events leading to discontinuation or death; coded by system organ class and preferred term. Unit: participants.

    Time frame: From randomization (Day 1) through end of follow-up (up to Day 189 ±3 days)

  2. Change From Baseline in Safety 12-Lead ECG QTcF

    Change from baseline in QT interval corrected using Fridericia's formula (QTcF) measured on single 12-lead safety ECGs. Unit: milliseconds (ms).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  3. Change From Baseline in Safety 12-Lead ECG PR Interval

    Change from baseline in PR interval measured on single 12-lead safety ECGs. Unit: milliseconds (ms).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  4. Change From Baseline in Safety 12-Lead ECG QRS Duration

    Change from baseline in QRS duration measured on single 12-lead safety ECGs. Unit: milliseconds (ms).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  5. Change From Baseline in Heart Rate (12-Lead Safety ECG)

    Change from baseline in heart rate measured on single 12-lead safety ECGs. Unit: beats per minute (bpm).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  6. Change From Baseline in ALT

    Change from baseline in alanine aminotransferase. Unit: U/L.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  7. Change From Baseline in AST

    Change from baseline in aspartate aminotransferase. Unit: U/L.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  8. Change From Baseline in Total Bilirubin

    Change from baseline in total bilirubin. Unit: mg/dL.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  9. Change From Baseline in Serum Creatinine

    Change from baseline in serum creatinine. Unit: mg/dL.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  10. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR; CKD-EPI 2021)

    Change from baseline in eGFR calculated using CKD-EPI 2021. Unit: mL/min/1.73 m².

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  11. Change From Baseline in INR

    Change from baseline in international normalized ratio- (INR). Unit: unitless.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  12. Change From Baseline in Prothrombin Time (PT)

    Change from baseline in prothrombin time. Unit: seconds (s).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  13. Change From Baseline in Activated Partial Thromboplastin Time (aPTT)

    Change from baseline in aPTT. Unit: seconds (s).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  14. Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR)

    Change from baseline in UACR (geometric mean of triplicates at each visit). Unit: mg/g.

    Time frame: Baseline (Day -1) and scheduled visits through Day 189 ±3 days; UACR as triplicate first-morning voids per visit

  15. Change From Baseline in Systolic Blood Pressure

    Change from baseline in supine systolic blood pressure. Unit: mmHg.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  16. Change From Baseline in Diastolic Blood Pressure

    Change from baseline in supine diastolic blood pressure. Unit: mmHg.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  17. Change From Baseline in Heart Rate (Vital Signs)

    Change from baseline in supine heart rate. Unit: bpm.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  18. Change From Baseline in Body Temperature

    Change from baseline in oral body temperature. Unit: °C.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  19. Change From Baseline in Respiratory Rate

    Change from baseline in respiratory rate. Unit: breaths per minute.

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

  20. Change From Baseline in Oxygen Saturation (SpO2)

    Change from baseline in pulse oximetry oxygen saturation. Unit: percent (%).

    Time frame: Baseline (Day -1) and post-dose at scheduled visits through Day 189 ±3 days

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of AZD1613

    Maximum observed serum concentration following subcutaneous or intravenous administration. Unit: µg/mL.

    Time frame: Intensive PK sampling from Day 1 through Day 189 per protocol schedule

  2. Area Under the Concentration-Time Curve to Last Quantifiable Concentration (AUClast) of AZD1613

    AUC from time zero to last quantifiable concentration. Unit: h·µg/mL (or day·µg/mL; align with bioanalytical report).

    Time frame: Intensive PK sampling from Day 1 through Day 189 per protocol schedule

  3. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of AZD1613

    AUC from time zero extrapolated to infinity. Unit: h·µg/mL (or day·µg/mL).

    Time frame: Intensive PK sampling from Day 1 through Day 189 per protocol schedule

  4. Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUCtau) of AZD1613

    AUC over the dosing interval at steady state. Unit: h·µg/mL (or day·µg/mL).

    Time frame: Over the dosing interval (τ = 28 days) at steady state; sampling through Day 189

  5. Time to Maximum Observed Serum Concentration (Tmax) of AZD1613

    Time to reach Cmax after dosing. Unit: hours (h).

    Time frame: Intensive PK sampling from Day 1 through Day 189 per protocol schedule

  6. Terminal Elimination Half-Life (t½) of AZD1613

    Half-life associated with terminal slope (λz) of the concentration-time curve. Unit: hours (h) or days (d).

    Time frame: Intensive PK sampling from Day 1 through Day 189 per protocol schedule

  7. Incidence of Anti-Drug Antibodies (ADA) to AZD1613

    Number of participants with ADA-positive response based on validated tiered assay (screen and confirm). Unit: participants.

    Time frame: Predose on dosing days and during follow-up through Day 189 ±3 days

  8. ADA Titer to AZD1613

    Titer among confirmed ADA-positive samples. Unit: reciprocal dilution (titer).

    Time frame: Predose on dosing days and during follow-up through Day 189 ±3 days

  9. Change From Baseline in PD Markers of PAPPA-1 Inhibition

    Change from baseline in pharmacodynamic marker of PAPPA-1 inhibition. Unit: ng/mL (or assay-specific unit).

    Time frame: Baseline to scheduled post-dose time points through Day 189 ±3 days

06

Study locations

7 of 15 sites recruiting
  • Research Site
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • Research Site
    Loma Linda, California 92354, United States
    Not yet recruiting
  • Research Site
    Jacksonville, Florida 32216, United States
    Recruiting
  • Research Site
    Orlando, Florida 32808, United States
    Recruiting
  • Research Site
    Lenexa, Kansas 66219, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21201, United States
    Not yet recruiting
  • Research Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Research Site
    San Antonio, Texas 78212, United States
    Not yet recruiting
  • Research Site
    Chengdu, 610072, China
    Not yet recruiting
  • Research Site
    Hangzhou, 310003, China
    Recruiting
  • Research Site
    Nanjing, 210009, China
    Recruiting
  • Research Site
    Shanghai, 200025, China
    Not yet recruiting
  • Research Site
    Wuhan, 430022, China
    Not yet recruiting
  • Research Site
    Xiamen, 361101, China
    Not yet recruiting
  • Research Site
    London, NW3 2QG, United Kingdom
    Recruiting
07

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07228364
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Nov 10, 2025
Primary completion
May 22, 2027 (estimated)
Completion
May 22, 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion